Matthias Guckenberger
Overview
Explore the profile of Matthias Guckenberger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
478
Citations
9579
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Volpe S, Vincini M, Zaffaroni M, Gaeta A, Raimondi S, Piperno G, et al.
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075755
An Early-Stage Non-Small Cell Lung Cancer (ES-NSCLC) patient candidate for stereotactic body radiotherapy (SBRT) may start their treatment without a histopathological assessment, due to relevant comorbidities. The aim of this...
2.
Kretzschmar L, Gabrys H, Joye A, Kraft J, Guckenberger M, Andratschke N
Clin Exp Metastasis
. 2025 Feb;
42(2):16.
PMID: 39928239
Postoperative radiotherapy improves local control (LC) after resection of brain metastases. In comparison to whole brain radiotherapy (WBRT) stereotactic radiosurgery (SRS) to resection cavity significantly reduces cognitive side effects. However,...
3.
Lehrer E, Khunsriraksakul C, Garrett S, Trifiletti D, Sheehan J, Guckenberger M, et al.
Crit Rev Oncol Hematol
. 2025 Jan;
208:104631.
PMID: 39864534
There is much debate regarding optimal selection in patients with metastatic cancer who should undergo local treatment (surgery or radiation treatment) to the primary tumor and/or metastases. Additionally, the optimal...
4.
Nguyen T, Louie A, Kotecha R, Saxena A, Zhang Y, Guckenberger M, et al.
Radiother Oncol
. 2025 Jan;
205:110717.
PMID: 39862925
Background: While SBRT to NSBM has become common, particularly in the oligometastatic population, the approach to treating non-spine bone metastases (NSBM) with stereotactic body radiotherapy (SBRT) varies widely across institutions...
5.
Le Guevelou J, Sargos P, Ost P, Alongi F, Arcangeli S, Berlin A, et al.
Clin Transl Radiat Oncol
. 2025 Jan;
51():100907.
PMID: 39845565
Purpose: In prostate cancer patients, high radiation doses to the urethra have been associated with an increased risk of severe genitourinary toxicity following dose-escalated radiotherapy. Urethra-sparing techniques have emerged as...
6.
Murthy V, Marvaso G, Jereczek-Fossa B, Thoma S, Vogel M, Schmidt-Hegemann N, et al.
Eur Urol
. 2025 Jan;
PMID: 39837736
The Co-IMPACT consortium addresses knowledge gaps in prostate-specific membrane antigen positron emission tomography-guided radiotherapy for prostate cancer by establishing a global database (46 centres from 16 countries) to standardise and...
7.
Regnery S, Katsigiannopulos E, Lau H, Hoegen-Sassmannshausen P, Weykamp F, Renkamp C, et al.
Clin Transl Radiat Oncol
. 2025 Jan;
51():100899.
PMID: 39790128
Purpose: To use imaging data from stereotactic MR-guided online adaptive radiotherapy (SMART) of ultracentral lung tumors (ULT) for development of a safe non-adaptive approach towards stereotactic body radiotherapy (SBRT) of...
8.
Kirschner M, Meerang M, Orlowski V, Furrer K, Tschanz F, Grgic I, et al.
JTCVS Open
. 2025 Jan;
22():491-503.
PMID: 39780777
Objective: To test the safety and efficacy of combination treatment for pleural mesothelioma (PM) with intracavitary cisplatin-fibrin (cis-fib) plus hemithoracic irradiation (IR) applied after lung-sparing surgery in an orthotopic immunocompetent...
9.
Weller M, Le Rhun E, Tsamtsouri L, Dummer R, Guckenberger M, Ribi K, et al.
Lung Cancer
. 2024 Dec;
199:108069.
PMID: 39731865
No abstract available.
10.
Houda I, Bahce I, Dickhoff C, Kroese T, Kroeze S, Mariolo A, et al.
Lung Cancer
. 2024 Dec;
199:108061.
PMID: 39705827
Introduction: The EORTC-Lung Cancer Group initiated a Delphi consensus process to establish a consensual definition of resectable stage III non-small cell lung cancer (NSCLC) for the use in clinical trials,...